34 results about "High insulin" patented technology

The present disclosure relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present disclosure, an NF microwell array membrane was fabricated by applying a molding process to an electrospun, permeable, biodegradable polycaprolactone (PCL) NF membrane and thus allows gases and soluble factors to permeate therethrough. The NF microwell of the present disclosure could provide more nutrients to the iPSC aggregates than conventional impermeable PDMS microwells, thus enhancing survival and differentiation capabilities of the cells. Additionally, the NF membrane was attached singly to the subcutaneous tissue and to the surface of organs such as liver and peritoneum without the need for a fixing material or separate sutures and was integrated with surrounding tissues, resulting in higher insulin secretion than PDMS microwells. Therefore, the present disclosure can be effectively utilized as a composition for the prevention or treatment of diabetes.

The main objective of this invention is to provide a novel manufacturing method capable of efficiently and directly converting or inducing somatic cells into insulin-producing cells. As an example, a method for manufacturing insulin-producing cells is provided, which involves directly differentiating and inducing insulin production from somatic cells. This method includes a step of culturing somatic cells in a serum-free differentiation-induction medium; or a step of culturing somatic cells in a differentiation-induction medium containing 5 μg / mL or more of insulin. According to this invention, insulin-producing cells with high insulin secretion capacity can be efficiently and directly manufactured from somatic cells. The insulin-producing cells obtained by this invention are useful in regenerative medicine and the like.

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The invention relates to mulberry oligosaccharide, a preparation method thereof and application of the mulberry oligosaccharide in blood sugar regulation and control. The mulberry oligosaccharide is obtained by processing mulberries through a large number of researches and specific process steps of enzymolysis, selenic acid modification, plasma treatment and the like, so that the stability of the mulberry oligosaccharide can be obviously improved, the inhibition capability on alpha-glucosidase is obviously improved, the sugar tolerance condition of diabetic mice is improved, the blood sugar level is stabilized, and the application prospect is wide. Meanwhile, the insulin sensitivity of the body can be improved, the insulin resistance degree can be improved, the absorption and utilization of insulin to glucose can be improved, the SOD activity of the body can be improved, and the MDA content can be reduced, so that the development of diabetes can be effectively slowed down. In addition, natural mulberry is used as a main preparation raw material, no harmful chemical component is added, the cost is low, the safety is good, and great social significance is achieved.

The invention belongs to the technical field of drug synthesis, and provides an EGC-based glutamate dehydrogenase degradation agent which comprises a structural general formula I, II or III. A series of conjugates of EGC and a protein degradation targeting chimera are synthesized to achieve the effect of intracellular GDH protein degradation, and GDH protein degradation can prevent degradation of a large amount of glutamic acid, so that toxicity to nerve cells caused by generation of a large amount of ammonia is prevented; and a new strategy is provided for treatment of rare diseases of the high insulin-hyperamminemia syndrome and treatment of other diseases related to high expression of GDH. In order to improve the biological activity of a GDH inhibitor, the invention provides a series of degradation agents based on a PROTAC technology, namely EGCG and EGC derivatives, the degradation agents comprise protein degradation targeting chimera molecules, and GDH protein is more effectively degraded by utilizing an intracellular ubiquitin proteasome system.

The application discloses a kind of SNX9 engineering mitochondria vesicles and its preparation method and application in improving insulin resistance.The application first constructs the vector of overexpression SNX9 gene, transfects cell, obtains stable overexpression SNX9 gene cell strain, culture, collects culture solution, obtains SNX9-MDVs by centrifugal separation;Then mtDNA is extracted from cell and introduced into SNX9-MDVs, to obtain the engineering mitochondria vesicles mtDNA-SNX9-MDVs rich in mtDNA.MtDNA-SNX9-MDVs are used for insulin resistance treatment, and the results show that mtDNA-SNX9-MDVs can effectively increase mitochondrial ATP and mtDNA content, enhance cell antioxidant enzyme activity, reduce ROS, improve mitochondrial network structure, increase the expression of insulin signal pathway related proteins, and show obvious mitochondrial function repair potential and insulin resistance improvement effect.

Disclosed herein are methods of treating and ameliorating hyperinsulin hypoglycemia using sodium dependent glucose transporter (SGLT) 1 inhibitor compounds and compositions comprising them.

The invention discloses an application of a betaine-lactic acid deep eutectic solvent in promotion of protein intestinal absorption and an application in preparation of a protein intestinal absorption promoting agent. In the betaine-lactic acid eutectic solvent, the molar ratio of betaine to lactic acid is 1: (0.5-1.5). The invention further discloses a protein intestinal tract promoting absorbent which is composed of insulin, betaine and lactic acid, the concentration of the insulin is 2-5 mg / ml, and the molar ratio of the betaine to the lactic acid is 1: (0.5-1.5). According to the invention, model protein insulin is loaded by BL-DES, so that the intestinal absorption efficiency of insulin can be improved. The BL-DES stabilizes the insulin structure through the interaction of hydrogen bonds, Van der Waals' force and static electricity, reduces the viscosity of intestinal mucus, promotes model protein insulin bypass transport by reversibly opening epithelium tight connection, and significantly improves the transmembrane transport efficiency and oral bioavailability of protein. The research of the invention is of great significance to oral protein treatment.

The invention is applicable to the technical field of biological medicines, provides application of ophiopogon japonicus borneol glycoside in preparation of a medicine for preventing and treating gestational metabolic diseases, and aims to solve the technical problems that the conventional medicine is limited in use during pregnancy, and the curative effect and the safety are difficult to take into account. According to verification of multi-model systems such as animals, cells and human-derived trophoblast organs, it is found that ophiopogon japonicus borneol glycoside can significantly improve gestational glycometabolism disorder, improve insulin sensitivity and reduce insulin resistance, and therefore effective intervention on gestational diabetes mellitus is achieved. As a natural component derived from the Zhejiang radix ophiopogonis, the radix ophiopogonis borneol glycoside has definite pharmacological activity and excellent safety, and the Zhejiang radix ophiopogonis is listed in a national homology of medicine and food, so that reliable safety guarantee is provided for use during pregnancy.

The application discloses a mesenchymal stem cell preparation expressing FOXO3 and FGF21 and application thereof, relates to biological medicine, and a parent plasmid carrying a therapeutic gene of the mesenchymal stem cell expressing FOXO3 and FGF21 has a nucleotide sequence as shown in SEQ ID No: 01; the application provides a mesenchymal stem cell preparation capable of simultaneously expressing FOXO3 and FGF21, which can effectively improve insulin glucose tolerance, effectively reduce the content of glycosylated hemoglobin, and has the potential to treat human type 2 diabetes.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The invention discloses application of pancreatic protein peptide in preparation of products for improving insulin resistance and repairing pancreatic functions, and relates to the technical field of biological medicines. The pancreatic-derived protein peptide is extracted and purified from porcine pancreatic tissue through a specific enzymolysis process, the molecular weight is concentrated at 800-2000Da, and the pancreatic-derived protein peptide contains 12 essential amino acids. Experiments prove that the protein peptide can significantly improve insulin sensitivity and promote pancreatic beta cell proliferation through oral administration or intraperitoneal injection, and has no obvious toxic or side effect. The invention provides a novel treatment means for diseases related to type 2 diabetes and pancreatic function impairment, and has a wide clinical application prospect.

The present disclosure describes a closed-loop control system based on glucose prediction, and related methods and apparatus, a control device of the closed-loop control system configured to determine a current glucose concentration, detect a training condition, retrieve stored glucose data for a first predetermined period of time in response to triggering of the training condition, and control the stored glucose data for a second predetermined period of time. Retrieving insulin delivery data in a second predetermined time period, processing the heart rate data in the first predetermined time period to obtain a heart rate statistical value, processing the body temperature data in the first predetermined time period to obtain a body temperature statistical value, and updating a prediction model based on the stored glucose data, the insulin delivery data, the heart rate statistical value and the body temperature statistical value, based on the current glucose concentration, the data related to the current glucose concentration and the updated prediction model, a glucose prediction value corresponding to the current glucose concentration is obtained, and the insulin dosage provided by the infusion device is determined based on the glucose prediction value. According to the invention, the correctness of the insulin dosage can be improved.

The present invention belongs to the technical fields of protein and genetic engineering. Specifically, it discloses the use of erythropoietin-producing hepatocyte receptor B4 as a target in screening and preparing biological agents or drugs for increasing insulin sensitivity. It also discloses the use of erythropoietin-producing hepatocyte receptor B4 in generating an insulin-sensitized mouse model. Based on the regulation of insulin signaling, a protein, EphB4, capable of interacting with the insulin receptor (InsR), was discovered. This protein can interact with InsR, and insulin stimulation can promote the interaction between the two, which provides a basis for insulin resistance in cases of hyperinsulinemia. Overexpression of EphB4 can promote the degradation of InsR, while suppression of EphB4 can increase insulin sensitivity and improve insulin resistance.

The invention relates to the technical field of biology, in particular to a method for treating insulin analogues through sequential enzyme digestion so as to improve the enzyme digestion yield. The method comprises the step of carrying out specific enzyme digestion on the proinsulin analogue by using recombinant double-base amino acid endopeptidase (Kex-2 enzyme) and recombinant trypsin in sequence, and comprises the following steps: firstly, adding the Kex-2 enzyme to perform enzyme digestion on double bases between Linker-A chains to generate an intermediate peptide 1, and then adding the recombinant trypsin to cut a guide peptide and a connecting peptide to obtain a target product. According to the method, the enzyme digestion yield can be remarkably increased by 25% or above, meanwhile, miscut impurities generated by single recombinant trypsin enzyme digestion are avoided, and the method is suitable for efficient enzyme digestion in insulin analogue production.

The application belongs to the technical field of food health, and particularly relates to a rice peptide which is helpful to reducing blood sugar and application thereof. The application takes rice protein as raw material, and establishes a rice peptide preparation method through protein enzyme screening, single factor experiment and response surface method optimization of enzyme hydrolysis process. The combination of T2DM model evaluation of the blood sugar reducing activity shows that the part of the rice peptide with a molecular weight of less than 1000 Da reaches more than 90%, can effectively relieve the glucose metabolism disorder of T2DM mice, can significantly reduce the fasting blood glucose and HbA1c level of T2DM mice, wherein 500 mg / kg.bw rice peptide can reduce the blood sugar by 23.36%; can improve insulin resistance and improve the sensitivity of insulin; can relieve the pancreatic injury, repair the islet structure, and reduce the liver fatty degeneration; can significantly increase the serum GLP-1 level of T2DM mice by 7.29%, and reduce the serum DPP-IV by 8.84%.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

The invention relates to the field of stem cell culture, in particular to adiponectin gene modified mesenchymal stem cells as well as a preparation method, a medicine and application thereof. The adiponectin gene modified mesenchymal stem cell provided by the invention can overexpress adiponectin to stimulate islet cells, regulate sugar stimulation response and improve insulin secretion amount. The preparation method of the adiponectin gene modified mesenchymal stem cell provided by the invention is simple, and the prepared adiponectin gene modified mesenchymal stem cell is higher in insulin secretion amount and longer in action time in an INS-1 cell sugar stimulation experiment.

The application is a bifunctional cyclic peptide which reduces insulin and does not increase blood sugar but appropriately reduces blood sugar, and belongs to the technical field of biological medicine. 52‑69 The cyclic peptide is obtained by in-vitro modification and reformation on the basis of the original linear short peptide COX The application realizes the seemingly contradictory two aspects of functions, i.e. inhibiting insulin secretion while not increasing blood sugar, and even reducing blood sugar, and the mechanism may be that the sensitivity of the tissue to insulin is improved. We call it a bifunctional peptide. The bifunctional peptide can be used for congenital hyperinsulinemia, insulin resistance, high insulin of obese people, etc. Literature reports that the increase of insulin is the cause of obesity, but for a long time, we cannot reduce weight by reducing insulin because the blood sugar will increase after the reduction of insulin, and high blood sugar is more harmful to health. The cyclic peptide realizes the function of reducing insulin while the blood sugar does not increase, but is reduced, which opens up a new way for weight loss of obesity, and the peptide can be conveniently administered orally in addition to injection. The convenience of use is greatly improved.

The invention discloses an SNX9 engineered mitochondrial vesicle, a preparation method thereof and application of the SNX9 engineered mitochondrial vesicle in improvement of insulin resistance. The preparation method comprises the following steps: firstly, constructing a carrier for overexpressing an SNX9 gene, transfecting cells to obtain a cell strain for stably overexpressing the SNX9 gene, culturing, collecting a culture solution, and centrifugally separating to obtain SNX9-MDVs; and then, extracting mtDNA from the cells, and introducing the mtDNA into the SNX9-MDVs, so as to obtain the engineered mitochondrial vesicle mtDNA-SNX9-MDVs rich in the mtDNA. The mtDNA-SNX9-MDVs is used for treating insulin resistance, and the result shows that the mtDNA-SNX9-MDVs can effectively increase the content of ATP and mtDNA of mitochondria, enhance the activity of cell antioxidant enzyme, reduce ROS, improve the mitochondrial network structure and improve the expression of insulin signal channel related protein, and shows obvious mitochondrial function repair potential and insulin resistance improvement effect.

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

The utility model belongs to the technical field of insulin injection, and particularly relates to an insulin injection training device which comprises an auxiliary training paste, the auxiliary training paste is provided with four injection areas, the auxiliary training paste is attached to the injection areas for training according to the four injection areas, the auxiliary training paste is provided with four indicating concave cavities, and the indicating concave cavities are communicated with the auxiliary training paste. The four indicating concave cavities are located in the four injection areas correspondingly, and a plurality of movable identification rods are connected into the indicating concave cavities in a sliding mode; the movable marking rod can be operated in the indicating concave cavity to play a role in indicating, the movable marking rod facing an injection area is screwed under the action of the connecting stud, the outer rounding sleeve can be located in the indicating concave cavity for indicating, the numbers of the annotation label are exposed, and then insulin injection can be carried out according to the sequence of the numbers. A trained patient can be prevented from injecting the same part according to the auxiliary training paste, the patient can clearly know the injection area every time the patient uses the auxiliary training paste, and the insulin injection effect is improved.

The present invention relates to a synergistic herbal formulation comprising standardised extracts of Berbens aristata and Phyllanthus emblica for the management of elevated blood glucose levels, insulin resistance, prediabetes, and type 2 diabetes mellitus. The formulation includes Berberis aristata extract containing 1% to 30% berberine and a whole extract of Phyllanthus emblica comprising tannins, gallic acid, and ellagic acid. In preferred embodiments, lecithin is incorporated to enhance the bioavailability of berberine through phospholipid complexation. The invention also provides a scalable method for preparing the formulation using hydroalcoholic extraction and lyophilisation. The formulation demonstrates dual activity: reducing glucose levels and enhancing insulin sensitivity via PPAR-y modulation. Preclinical and clinical studies confirm its efficacy and safety. The formulation is suitable for oral administration in various dosage forms and offers a natural, steroid-free alternative to conventional antidiabetic agents. The invention further includes therapeutic kits and methods for treating metabolic disorders.

The present invention relates to a synergistic herbal formulation comprising standardised extracts of Berbens aristata and Phyllanthus emblica for the management of elevated blood glucose levels, insulin resistance, prediabetes, and type 2 diabetes mellitus. The formulation includes Berberis aristata extract containing 1% to 30% berberine and a whole extract of Phyllanthus emblica comprising tannins, gallic acid, and ellagic acid. In preferred embodiments, lecithin is incorporated to enhance the bioavailability of berberine through phospholipid complexation. The invention also provides a scalable method for preparing the formulation using hydroalcoholic extraction and lyophilisation. The formulation demonstrates dual activity: reducing glucose levels and enhancing insulin sensitivity via PPAR-y modulation. Preclinical and clinical studies confirm its efficacy and safety. The formulation is suitable for oral administration in various dosage forms and offers a natural, steroid-free alternative to conventional antidiabetic agents. The invention further includes therapeutic kits and methods for treating metabolic disorders.

The present invention relates to modified glucagon peptides with increased specificity, high solubility and increased potency to a GCG receptor. In particular, the modified glucagon peptides of the present invention are used in the prevention and / or treatment of hypoglycemia, including acute, sub-acute, chronic hypoglycemia, post-bariatric hypoglycemia, congenital hyperinsulinism, body weight control, liver fat (lipid) metabolism, other lipid parameter control, treatment of Type 2 diabetes, or protein load renoprotection.

The application discloses a kind of flavonoids with the synergistic effect of reducing sugar and its preparation method and application, belong to functional food and microbial technology field.The synbiotic comprises plant lactobacillus N107 live bacteria and rhizoma polygonati polysaccharide ferment, and the ferment is prepared from the crude polysaccharide of raw rhizoma polygonati fermented by homologous bacteria under optimized conditions.After fermentation, the molecular weight of polysaccharide is reduced by more than 70%, the reducing sugar is significantly improved, and butyric acid is produced.In vitro hypoglycemic activity analysis shows that the synbiotic can significantly inhibit alpha-glucosidase activity;Cell experiment shows that it can significantly improve the glucose uptake rate of insulin-resistant HepG2 cells;Mechanically, it inhibits gluconeogenesis and promotes Glut4 translocation through PI3K / Akt / FoxO1 pathway.The present application directly uses raw rhizoma polygonati polysaccharide, avoids degradation by cooking, realizes green biotransformation of polysaccharide and synergistic hypoglycemic effect of synbiotic, has the advantages of probiotics and prebiotics, and the polysaccharide utilization rate is high.

The present application relates to a kind of Bacteroides in lowering blood sugar. Specifically, the present application provides a kind of Bacteroides plebeius J2525 with the function of lowering blood sugar, which is a strain of gram-negative bacteria isolated and purified from human feces, which has been preserved in China General Microbiological Culture Collection Center (CGMCC) on April 25, 2025, and the preservation number is CGMCC NO.46398. The present application also provides the use of Bacteroides plebeius J2525 of the present application in the preparation of products for lowering blood sugar, improving glucose tolerance or improving insulin sensitivity. The present application shows that Bacteroides plebeius strain J2525 can be developed as a kind of probiotics with good blood sugar lowering effect, and has high reference value for the application of the strain in clinic.

The invention belongs to the technical field of resource utilization of medicinal aloe protein, and particularly relates to medicinal aloe hypoglycemic polypeptide as well as a preparation method and application thereof. The medicinal aloe is aloe barbadensis, and the sequence of the medicinal aloe hypoglycemic polypeptide is WSPE and WDPF. Aloe vera is used as a starting material, an enzymolysis technology is adopted to prepare aloe polypeptide, a gel chromatographic column is further utilized for separation and purification, and the purified polypeptide component is subjected to mass spectrum identification. Cytology experiment research finds that the two aloe enzymolysis polypeptides WSPE and WDPF prepared by the method disclosed by the invention can be used for remarkably improving the consumption of glucose by insulin-resistant HepG2 cells. Therefore, the aloe polypeptides WSPE and WDPF can be used as effective components for preparing medicines or health care products with the hypoglycemic effect and have important application value, and a foundation is laid for high-value utilization of medicinal aloe.

This invention provides a ginger active ingredient composition and its application. The ginger active ingredient composition includes acetylated 12-gingerol, 8-gingereneol, and 10-gingereneol in a mass ratio of (1-3):2:(2-3). The ginger active ingredient composition of this invention can improve glucose tolerance, increase insulin sensitivity, reduce serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, increase high-density lipoprotein levels, reduce the activity of hepatic alanine aminotransferase and aspartate aminotransferase, improve the degree of hepatic fat vacuolar lesions, and reduce the content of lipid metabolism-related metabolites in obese individuals. Simultaneously, acetylation of 12-gingerol improves its lipid solubility, enhances cell membrane penetration, reduces oxidative degradation of phenolic hydroxyl groups, and improves stability. Furthermore, it releases free 12-gingerol after enzymatic hydrolysis, achieving a sustained-release effect.

The present invention relates to a composition for increasing insulin sensitivity or ameliorating insulin resistance, comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient, and a use thereof. More specifically, the present invention relates to a composition for increasing insulin sensitivity or ameliorating insulin resistance, comprising 1,1-diethoxyethane as an active ingredient as a PTEN oxidative inhibitor, and a use thereof, for example, a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition as a composition for preventing, treating, or ameliorating diseases related to insulin resistance.